Creo Medical was founded in 2003 as MicroOncology Ltd by Professor Chris Hancock, initially to target the treatment of cancers through use of high frequency microwave energy and dynamic matching techniques. The business strategy subsequently evolved to develop minimally invasive electrosurgical endoscopic devices with wider applications, and was rebranded as Creo Medical in 2010 to reflect this.

The Company’s devices are each enabled by its multi-patented CROMA platform, powered by Kamaptive – Creo’s full-spectrum adaptive advanced energy source which optimises surgical capability and patient outcomes. The multi-patented Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions.

CROMA is currently used to deliver bipolar radiofrequency energy for precise localised cutting and focused high frequency microwave energy for controlled coagulation and ablation via a single accessory port. Now in every-day in Europe, APAC and the US, this technology, combined with the Group’s range of unique electrosurgical devices, is facilitating a paradigm shift from surgery to endoscopic treatment – having already successfully removed cancerous lesions in the colon, stomach and elsewhere.